management
THOMAS ZINDRICK, JD
Executive Chairman
Trevor thompson
President
Mr. Thompson joined Aeromics as Chief Operating Officer after first serving Aeromics as a business development consultant through Pullan Consulting where he works with clients on their financing and partnering strategy execution. In 2020, Mr. Thompson was named President of the company. Prior to Pullan Consulting, Mr. Thompson was the VP of Corporate Development for Abeome, a small biotechnology company focused therapeutic antibodies and brings over 15 years of finance and operations experience to the role of COO for Aeromics.
JOSEPH SCHINDLER, MD
Chief Medical Officer
Dr. Schindler is a nationally recognized stroke expert and has served as a principal investigator on many clinical trials studying novel therapeutics for acute stroke and secondary prevention. Dr. Schindler serves as the Clinical Chief of the Division of Stroke and Vascular Neurology at Yale University School of Medicine where he is an Associate Professor of Neurology and of Neurosurgery. He serves as the Director of the Comprehensive Stroke Center at Yale-New Haven Hospital and is the founding Director of the Yale New-Haven Telestroke Service which has greatly extended access to stroke services throughout the state of Connecticut. Additionally, he is the Director of the Vascular Neurology Fellowship Program at Yale-New Haven Hospital & Yale University School of Medicine.
DAVE JENKINS
VP Finance
Mr. Jenkins is a retired Big 4 audit partner with deep finance, accounting, SEC reporting and transaction experience and joined Aeromics in 2019. He has a 30 year track record of assisting companies develop strategies, work through complex business problems, complete transactions and establish strong business processes and systems.
board of directors
JEFFREY P. DRAIME
Chairman Emeritus
Mr. Draime served as Aeromics’ Chairman from October 2017 to July 2020. Jeff is the son of D.M. Draime, the founder of Stoneridge, Inc. (NYSE: SRI) and has served in various roles with Stoneridge prior to serving as a member of their Board of Directors, a position he has held since 2004. He also currently holds positions on the Compensation, Nominating and Governance Committees. Mr. Draime provides independent business consulting services and serves as President of AeroMax Aviation Holdings, LLC.
THOMAS ZINDRICK, JD
Executive Chairman
Mr. Zindrick was elected to the position of Executive Vice Chairman at Aeromics in March 2019 and Executive Chairman in July 2020, and is responsible for strategic business operations at Aeromics. Mr. Zindrick brings over 25 years of executive experience in the life sciences and biotechnology and also currently serves as President & Chief Executive Officer of Genelux Corporation since 2014. Mr. Zindrick retired from Amgen, Inc. in 2009 after a distinguished 16-year career. While at Amgen, he held positions of increasing responsibility, including Vice President, Associate General Counsel and Chief Compliance Officer. As Vice President, Associate General Counsel, Mr. Zindrick led intellectual property, licensing and regulatory law teams and served on cross-functional business and product development teams. These teams were responsible for acquisitions totaling over $20 billion and the licensing and development of six therapeutic products and numerous clinical candidates. As Chief Compliance Officer, he reported to the Board of Directors and led the Corporate Compliance Program, which oversaw the compliance activities of numerous company functions including product development, manufacturing and marketing.
PETER AGRE, MD
Science & Technology Committee Chairman
Dr. Agre is a Bloomberg Distinguished Professor at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine, and Director of the Johns Hopkins Malaria Research Institute. Dr. Agre served as President of the American Association for the Advancement of Science (2009-10). In 2003, Agre shared the Nobel Prize in Chemistry for his discovery of the Aquaporin water channels.
Dr. Agre was previously Professor of Medicine and Biological Chemistry at the Johns Hopkins School of Medicine (1992-05), Vice Chancellor for Science and Technology at Duke Medical Center (2005-07), and he served as President of the American Association for the Advancement of Science (2009-10). He received clinical training in internal medicine and hematology and basic science training in cellular and molecular biology. His research has focused upon molecular aspects of human diseases, including hemolytic anemias, blood group antigens, and malaria.
Dr. Agre received his B.A. in Chemistry from Augsburg College in Minneapolis and his M.D. in 1974 from the Johns Hopkins School of Medicine in Baltimore, Maryland.
PETER LONGO, CPA, CFA
Mr. Longo is the Senior Managing Director of Investments at Connecticut Innovations, Inc. (CI) and has spent over 23 years in numerous roles at CI. Mr. Longo is currently responsible for evaluating investment opportunities, structuring investments and monitoring portfolio companies through active board participation. Peter’s past CI investments include: Achillion Pharmaceuticals (IPO), Cardium Health (acquired by Centene), CYA Technologies (acquired by enChoice), eTouches (acquired by HGGC), NeuVis (acquired by Rational Software), Nufern (acquired by Rofin-Sinar), SilverSky (acquired by BAE Systems), PCC Technology Group (acquired by Clearview Capital) and Post-N-Track.